- Home
- MCRB vs EPM Comparison
MCRB vs EPM Comparison
Compare MCRB & EPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCRB | EPM |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 140.7M | 124.2M |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MCRB | EPM |
|---|---|---|
| Price | $15.92 | $3.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $14.33 | $4.93 |
| AVG Volume (30 Days) | 60.6K | ★ 593.4K |
| Earning Date | 11-05-2025 | 02-10-2026 |
| Dividend Yield | N/A | ★ 13.52% |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | $351,000.00 | ★ $85,232,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.22 |
| P/E Ratio | $25.79 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.53 | $3.19 |
| 52 Week High | $29.98 | $5.70 |
Technical Indicators
Market Signals| Indicator | MCRB | EPM |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 50.66 |
| Support Level | $14.90 | $3.19 |
| Resistance Level | $16.00 | $3.42 |
| Average True Range (ATR) | 0.77 | 0.13 |
| MACD | 0.20 | 0.03 |
| Stochastic Oscillator | 82.78 | 87.74 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About EPM Evolution Petroleum Corporation Inc.
Evolution Petroleum Corp is an independent energy company focused on owning and investing in onshore oil and natural gas properties across the United States. Its portfolio includes non-operated interests in various production fields such as CO2 enhanced oil recovery in Louisiana, secondary recovery production in Wyoming, and shale gas reservoirs in Texas and North Dakota. The company generates revenue from the production and sale of oil and natural gas, leveraging specialized technologies to extend reservoir life and enhance recoveries.